Matregenix Inc.

Matregenix Inc., a minority-owned, self-certified small disadvantaged business manufacturer based in Mission Viejo, California, develops advanced nanofiber-based medical devices and biomaterials for military trauma care, wound healing, and tissue regeneration as a prime contractor under total small business set-asides and federal research grant programs. The company operates exclusively as a prime — 100% of its recent awards are prime contracts or grants with no subcontract footprint — and competes entirely under set-aside vehicles, with all ten Air Force Research Laboratory (AFRL) purchase orders designated as total small business set-asides and three National Institutes of Health (NIH) grants awarded to the company as direct recipient.

Matregenix's core capability centers on proprietary electrospinning technology to fabricate amino acid-based, biologically-free synthetic nanofiber membranes and devices designed for shelf stability, simplified logistics, and point-of-care deployment in military and clinical settings. Recent contract work includes a $1.797 million purchase order from AFRL (August 2024) for DERMASPIN, a handheld device for contactless application of an antibacterial nanofiber matrix for rapid wound healing; a $1.249 million SBIR Phase II contract from AFRL (August 2025) for a surge-capable, non-biologic amino acid-based wound-healing matrix for rapid trauma care; and a $1.249 million SBIR Phase II purchase order from AFRL (July 2025) for a streamlined synthetic amniotic membrane for ocular penetrating injuries and burns. On the grant side, Matregenix received a $314,211 award from the National Heart, Lung, and Blood Institute (September 2026) under the Cardiovascular Diseases Research program (CFDA 93.837) to develop biodegradable, drug-eluting nanofiber scaffolds for lymphatic regeneration and lymphedema treatment, and a July 2025 Phase II grant from the National Institute of Dental and Craniofacial Research (NIDCR) to establish the efficacy of MATRINOVA, a bilayered, animal-free amino acid-based membrane for guided bone regeneration targeting FDA 510(k) clearance.

Customer concentration is dominated by AFRL, which accounts for all ten contract awards (10 awards, $7.2 million combined potential value) spanning SBIR Phase I and Phase II efforts and purchase orders for battlefield dural repair, rotator cuff repair, and dental and craniomaxillofacial applications. NIH funding splits between NIDCR (two awards) and the National Heart, Lung, and Blood Institute (one award). Activity has grown from one award in 2022 to four annually in 2024 and 2025, with four awards (combined potential value $2.5 million) scheduled for completion within the next twenty-four months, including DERMASPIN and both rotator cuff nanofiber scaffold SBIR Phase II efforts. The company holds no positions on government-wide IDIQs, GWACs, or BPAs; all work flows through direct purchase orders and grant awards. Matregenix's award footprint reflects concentrated focus on defense medical innovation and regenerative medicine applications for federal research institutions, with no commercial or civilian-agency customer exposure in recent awards.